Management with Antithrombin III Concentrate in a Pregnant Woman with Hereditary Antithrombin III Deficiency

Abstract

Pregnant women with hereditary antithrombin III (AT-III) deficiency are frequently associated with thromboemblic disorders. We have treated a pregnant woman with hereditary AT-III deficiency, who had suffered from thromboemblic disorders at her past three gestations, with AT-III concentrate. Dosage of AT-III concentrate to maintain plasma AT-III activity over 80% was 3,500 units per week during second and third trimesters, but more frequent administration was necessary around delivery. In recent reports, pregnant women with hereditary AT-III deficiency had been treated with heparin or warfarin except for during abortion and delivery, in which time AT-III concentrate was widely utilized. But the use of heparin or warfarin during gestation is occasionally harmful, AT-III concentrate should be chosen for management in pregnancy in women with hereditary AT-III deficiency.